What is ELDN's market cap?

$219.41M, based on the Nov 4 close of $2.70.

Does Eledon Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ELDN is sold short?

7.9M shares, 9.7% of float, as of Oct 15, 2026.

What sector is ELDN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ELDNHealthcarePharmaceuticals

Eledon Pharmaceuticals, Inc. Common Stock (ELDN)

$2.70+3.05%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$2.70▼ 35.10% in range

Nov 4, 2025Low $1.39 · High $4.21Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Eledon Pharmaceuticals closed at $2.70 on Nov 4, up 3.05%, 38.1% below its 52-week closing high. Volume of 511.5K shares was 0.55× its 20-day average (below normal).

Split-adjusted performance: +10.2% over one month, -28.9% over six months, -38.1% over one year.

Short interest was 7.9M shares at the Oct 15 settlement (9.7% of float, 10.2 days to cover).

Market cap$219.4M81.3M shares

Revenue · quarter$0.00—

Diluted EPS$-0.27—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.39 – 4.36−38.1% from high

Volume511.5K0.55× 20-day avg

Volatility · 60d61.6%Annualised

Short % of float9.7%10.3 days to cover

Net cash$88.8MCash $88.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.2%1M +10.2%3M −22.0%6M −28.9%YTD +78.8%1Y −38.1%3Y +70.9%5Y −45.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum46

Revenue growth—

Net margin—

Value (low P/E)—

Size49

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short7.9M+0.6% vs prior

Days to cover10.3Settled Oct 15

% of float9.7%

Short vol. 10d63.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ELDNEledon Pharmaceuticals	$2.70	+3.05%	−28.9%	—	—	—	$219.4M
ADCTADC Therapeutics SA	$1.72	+10.97%	−55.4%	+2.2%	−86.1%	—	$219.6M	Compare
EVMNEvommune	$6.04	+1.68%	−74.7%	—	—	—	$219.2M	Compare
KROSKeros Therapeutics	$10.83	0.00%	−8.1%	−100.0%	—	—	$214.7M	Compare
NATRNature's Sunshine Products	$12.84	+6.38%	−51.1%	+1.9%	3.0%	12.5	$225.9M	Compare
SIGASIGA Technologies	$3.15	+1.29%	−33.0%	−49.5%	30.4%	—	$226.3M	Compare
RNACCartesian Therapeutics	$6.82	+6.40%	−18.2%	−100.0%	—	—	$206.3M	Compare
VNDAVanda Pharmaceuticals	$3.88	+3.47%	−47.8%	+24.1%	−32.3%	—	$234.6M	Compare
CAMPCAMP4 Therapeutics	$3.74	−2.35%	−7.9%	+18.8%	−1884.8%	—	$234.7M	Compare

News about Eledon Pharmaceuticals

All news →

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyGlobeNewswire Inc. · Sep 22, 2026▲ Positive

Quick answers

What does Eledon Pharmaceuticals do?: Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential.
What is ELDN's market cap?: $219.41M, based on the Nov 4 close of $2.70.
Does Eledon Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ELDN is sold short?: 7.9M shares, 9.7% of float, as of Oct 15, 2026.
What sector is ELDN in?: Healthcare, in the Pharmaceuticals industry.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

HQ: Irvine, CA33 employeesListed Sep 17, 2014eledon.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology